Nyxoah (NASDAQ:NYXH) Posts Earnings Results, Misses Expectations By $0.14 EPS

Nyxoah (NASDAQ:NYXH) posted its quarterly earnings results on Thursday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14), Zacks reports. Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%.

Nyxoah Price Performance

NASDAQ:NYXH traded down $0.58 on Thursday, hitting $5.31. The company had a trading volume of 36,614 shares, compared to its average volume of 94,087. Nyxoah has a 52 week low of $4.34 and a 52 week high of $11.87. The company has a current ratio of 2.63, a quick ratio of 2.38 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $180.86 million, a price-to-earnings ratio of -2.31 and a beta of 1.54. The firm has a 50 day moving average of $5.37 and a two-hundred day moving average of $6.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $14.50.

Institutional Investors Weigh In On Nyxoah

Several hedge funds have recently modified their holdings of NYXH. Shay Capital LLC bought a new position in Nyxoah in the second quarter valued at about $374,000. Raymond James Financial Inc. acquired a new position in shares of Nyxoah in the second quarter valued at approximately $70,000. Finally, Bank of America Corp DE increased its stake in shares of Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after buying an additional 3,303 shares during the period.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.